LCN2 and hepatocellular carcinoma: Remarkably, HCC patient-derived xenograft tumors often had low levels of LIFR and high levels of LCN2; when mice bearing these tumors were treated with sorafenib in combination with an LCN2-neutralizing antibody, a much better therapeutic response than sorafenib treatment alone was achieved.